Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO)

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 992-998

  Rau, B ^a   Schlag, P M ^a   Willeke, F ^b   Herfarth, Ch ^b   Stephan, P ^c   Franke, W ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Autologous blood donation; Recombinant human erythropoietin; Rectal cancer

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD DONOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ERYTHROCYTE VOLUME; FEMALE; HUMAN; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECTUM RESECTION; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

ADULT; AGED; BLOOD COMPONENT TRANSFUSION; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RECTAL NEOPLASMS; TRANSFERRIN;

EID: 0032100825     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00021-5     Document Type: Article

References (37)

1. Kühnl P., Löliger C., Laufs R. Blood-transfusion related infection risk. Chirurg. 65:1994;1071-1074.
2. Burrows L., Tartter P. Effect of blood transfusion on colonic malignancy recurrence rate (letter). Lancet. 2:1982;662.
3. Busch O.R., Hop W.C., Hoynck van Papendrecht M.A., Marquet R.L., Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 328:1993;1372-1376.
4. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994, 12, 1859-1867.
5. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994, 344, 573-578.
6. Vamvakas E., Moore S.B. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion. 33:1993;754-765.
7. Biesma D.H., Kraaijenhagen R.J., Poortman J., Marx J.J.M., van de Wiel A. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion. 32:1992;162-165.
8. Kickler T.S., Spivak J.L. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA. 260:1988;65-67.
9. Biesma D.H., Kraaijenhagen R.J., Marx J.J.M., van de Wiel A. The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy-induced anemia in autologous blood donors. Transfusion. 33:1993;825-829.
10. Goodnough LT, Rudnick S, Price TH, et al. Increased pre-operative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989, 321, 1633-1168.
11. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993, 33, 55-60.
12. Tasaki T., Ohto H., Hashimoto C., Abe R., Saitoh A., Kikuchi S. Recombinant human erythropoietin for autologous blood donation: effects on perioperative red-blood-cell and serum erythropoietin production. Lancet. 339:1992;773-775.
13. Blumberg N., Agarwal M., Chuang C. Relationship between recurrence of cancer of the colon and blood transfusion. Br Med J. 290:1985;1037-1039.
14. Hermanek P, Guggenmoos-Holzmann I, Schricker KT, et al. Influence of blood and hemoderivatives on the prognosis of colorectal carcinoma. Langenbecks Arch Chir 1989, 374, 118-124.
15. Hoynck van Papendrecht MA, Hop W, Langenhorst BL, et al. Feasibility of a predeposit autologous blood donation program in colorectal cancer patients: results from a randomized clinical study. Vox Sang 1992, 62, 102-107.
16. NIH. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264, 1444-1450.
17. Nadler S.B., Hidalgo J.U., Bloch T. Prediction of blood volume in normal human adults. Surgery. 51:1962;224-232.
18. Kientsch-Engel R, Hallermayer K, Dessauer A. Methods for measuring erythropoietin and erythropoietin antibodies using ELISA technique. In: Anonymous contributions to Nephrology, Erythropoietin: from molecular structure to clinical application. Basel, Karger, 1989, 100-105.
19. Blumberg N., Heal J.M. Transfusion and recipient immune function. Arch Pathol Lab Med. 113:1989;246-253.
20. Blajchman M.A., Bardossy L., Carmen R., Sastry A., Singal D.P. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood. 81:1993;1880-1882.
21. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993, 342, 1328-1333.
22. Steup WH, Hojo K, Moriya Y, et al. An analysis on the effect of blood transfusion on recurrence and survival in patients undergoing extended lymphadenectomy for colorectal cancer. Hepatogastroenterology 1994, 41, 253-259.
23. Waymack J.P., Chance W.T. Effect of blood transfusions on immune function: IV. Effect on tumor growth. J Surg Oncol. 39:1988;159-164.
24. Waymack J.P., Robb E., Alexander J.W. Effect of transfusion on immune function in a traumatized animal model: II. Effect on mortality rate following septic challenge. Arch Surg. 122:1987;935-939.
25. Mincheff M.S., Meryman H.T. Blood transfusion, blood storage and immunomodulation. Immunol Invest. 24:1995;303-309.
26. Blumberg N., Heal J.M. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med. 118:1994;371-379.
27. Watanabe Y, Fuse K, Konishi T, et al. Autologous blood transfusion with recombinant human erythropoietin in heart operations. Ann Thorac Surg 1991, 51, 767-772.
28. Heiss M.M., Mempel W., Delanoff C., Mempel M., Jauch K.W., Schildberg F.W. Clinical effects of blood transfusion-associated immune modulation on outcome of tumor surgery. Infusionsther Transfusionsmed. 20:(Suppl. 2):1993;25-29.
29. Stehling L, Luban NL, Anderson KC, et al. Guidelines for blood utilization review. Transfusion 1994, 34, 438-448.
30. Wasman J., Goodnough L.T. Autologous blood donation for elective surgery. Effect on physician transfusion behavior. JAMA. 258:1987;3135-3137.
31. Case DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. JNCI 1993, 85, 801-806.
32. Cazavane JP, Irrmann C, Waller C, et al. Epoetin alfa facilitates presurgical autologous blood donation in non-anaemic patients scheduled for orthopaedic or cardiovascular surgery. Eur J Anaesthesiol 1997, 14, 432-442.
33. Goldberg M.A. Perioperative epoetin alfa increases red blood cell mass and reduces exposure to transfusions: results of randomized clinical trials. Semin Hematol. 34:1997;41-47.
34. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996, 36, 29-36.
35. Goodnough L.T. The role of recombinant growth factors in transfusion medicine. Br J Anaesth. 70:1993;80-86.
36. Abraham PA, Halstenson CE, Macres MM, et al. Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies. Clin Pharmacol Ther 1992, 52, 205-312.
37. Macdougall I.C., Roberts D.E., Neubert G.A., Dharmasena A.D., Coles G.A., Williams J.D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet. 1:1989;425-427.